Skip to main content

Table 1 Effect of AL-1 on blood glucose level in alloxan-induced diabetic mice.

From: Hypoglycemic and beta cell protective effects of andrographolide analogue for diabetes treatment

Groups

Blood glucose level (mM)

Day 0

Day 6

Changes (%)

Normal control

5.8 ± 1.5

5.9 ± 1.7

+1.7

Diabetic control

27.0 ± 1.2 a

25.4 ± 7.8

-5.9

Diabetic + AL-1 (20 mg/kg)

24.9 ± 3.1a

16.8 ± 2.4 b

-32.5

Diabetic +AL-1 (40 mg/kg)

25.0 ± 2.7 a

13.9 ± 3.4 c

-44.4

Diabetic + AL-1 (80 mg/kg)

24.6 ± 3.2 a

8.6 ± 3.1 c, d

-65.0

Diabetic + Andro (50 mg/kg)

24.8 ± 3.0 a

16.8 ± 2.1 b

-32.3

Diabetic + Gli (1.2 mg/kg)

24.7 ± 5.1 a

10.1 ± 3.0 c, d

-59.1

  1. 72 h after alloxan administration (Day 0), drugs were given by intragastric administration once daily for 6 days. On day 0 and day 6, fasting blood glucose levels were determined. Values are means ± S.D. of 6 mice. aP < 0.01 vs. normal mice; bP < 0.05 vs. value on day 0; cP < 0.01 vs. value on day 0; dP < 0.05 vs. Andro treatment on day 6. Gli: glibenclamide.